Suppression of allograft rejection is central to successful organ transplantation; thus,
immunosuppressive agents are crucial for successful allograft function. Immunosuppressive …

The aim of this review is to analyse critically the recent literature on the clinical
pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplant recipients …

Background. Tacrolimus (FK506), a macrolide molecule that potently inhibits the expression
of interleukin 2 by T lymphocytes, represents a potential major advance in the management …

Diabetes mellitus is 1one of the most common chronic diseases in the world, with an
estimated worldwide prevalence of over 176 million in 2000. Furthermore, the prevalence of …

After the transplantation of unmodified marrow from human leukocyte antigen-matched
unrelated donors receiving cyclosporine (CSP) and methotrexate (MTX), the incidence of …

Objective To evaluate the long-term survival outcomes of a large cohort of liver transplant
recipients and to identify static and changing factors that influenced these outcomes over …

FTY720, given iv or orally at 0.03 mg/kg or more, significantly prolonged skin allograft
survival in a dose-dependent manner and showed more potent immunosuppressive activity …

Hepatic allograft rejection remains an important problem following liver transplantation, and,
indeed, complications related to the administration of immunosuppressive therapy remain a …

Background. To confirm the results of a number of studies conducted in Europe, the United
States, and Japan, this multicenter, randomized trial compared the 12-month efficacy and …

Background Tacrolimus (FK 506), a macrolide compound isolated from a bacterium, is a
potent immunosuppressant with activity in solid-organ transplants. Most immunosuppressive …